Auron is a platform-powered company targeting cell-state plasticity to improve patient outcomes in oncology and inflammatory disease. Auron uses AI and machine learning to compare cell states and identify novel drug targets, optimal development models, and biomarkers to facilitate proper patient selection, ultimately accelerating the development of effective and durable therapies.

Auron Therapeutics Inc
TAP Partner
Newtown, Massachusetts
United States
Project Title
A phase 1 study of AUTX-703, a KAT2A/B degrader, in patients with AML or MDS
Program
Therapy Acceleration Program